This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a single centre, before and after study. At the time of the analysis patients on maintenance IV-FeD had received treatment for a mean of 6 months with a range of 3 -15 months. No stated follow up time other than this is given. Patients were withdrawn from the study in the case of death, severe illness or transplantation if those events occurred within 3 months of starting maintenance IV-FeD. Numbers or proportions of such withdrawals were not given.
Analysis of effectiveness
Analysis was based on treatment completers only. Health outcomes measured were haemoglobin, serum ferritin and rHuEpo dose required. Measurements of these were taken at the onset and termination of the study period and the paired t-test used to determine statistical significance.
Effectiveness results
Mean haemoglobin before treatment was 87.7 g/l (S. D. 12.1). After treatment this rose to mean 100.3 (S. D. 13.6 g/l). The mean rise of 12.8 g/l was statistically significant (p <0.001, 95%CI 7.7-17.9). Mean serum ferritin rose from mean 36 mg/l (S. D. 20) to mean 217 mg/l (S. D. 127). This difference was significant (p <0.001, 95% CI 142-220). At the onset of treatment 19 patients(38%) were on rHuEpo and at the end of 6 months this was reduced to 17 with a further 8 patients needing a reduced dose. The mean weekly dose of in-patients on rHuEpo was reduced from 96 u/kg/week (S. D. 59) to 63 u/kg/week (S. D. 41). This was statistically significant, p <0.05, (CI 1-65).
No anaphylactic reactions or adverse effects were experienced. Nine patients had serum ferritin levels greater than 300 mg/l requiring a reduction in maintenance dose but no patient's ferritin level exceeded 500 mg/l.
Clinical conclusions
A regimen of maintenance intravenous iron treatment in the subset of haemodialysis patients for whom oral supplementation has failed was safe and effective when carefully monitored.
Measure of benefits used in the economic analysis
Health outcomes used were haemoglobin and serum ferritin levels. As the treatment was the dominant strategy the valuation was not defined. A target range of 100-200 mg/l was chosen for serum ferritin levels based on current available literature: Van Wyck D B (1984) , Van Wyck D B et al (1989), and Van Wyck D B (1991) . If no response in haemoglobin levels was perceived and transferrin saturation was less than 20% the goal was raised to 200-300 mg/l.
